PhoreMost Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 34
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $46M
Latest Deal Amount
  • Investors
  • 14

PhoreMost General Information

Description

Developer of a drug target identification platform intended to identify new targets or drugs for future therapy and also to remove the barriers for new drug development. The company's platform provides cryptic druggable sites in the human genome and directly link them to useful therapeutic functions in a live-cell context and then uses these functionally validated protein fragments to rapidly inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programmes for out-licensing to Pharma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Building 250
  • Babraham Research Campus, Cambridgeshire
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223 000000

PhoreMost Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PhoreMost Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 23-Mar-2021 $46M 000.00 Completed Generating Revenue
5. Early Stage VC (Series A) 30-Apr-2018 000.00 000.00 000.00 Completed Pre-Clinical Trials
4. Grant 27-Apr-2018 00.000 Completed Pre-Clinical Trials
3. Early Stage VC 03-Mar-2017 00.000 00.000 000.00 Completed Startup
2. Grant 13-May-2015 $2.14M $6.12M Completed Pre-Clinical Trials
1. Seed Round 11-Mar-2015 $6.12M $6.12M Completed Pre-Clinical Trials
To view PhoreMost’s complete valuation and funding history, request access »

PhoreMost Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 65,311 $0.001406 $54.69 $54.69 1x $54.69 16.71%
To view PhoreMost’s complete cap table history, request access »

PhoreMost Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug target identification platform intended to identify new targets or drugs for future therapy and also
Drug Discovery
Cambridge, United Kingdom
34 As of 2021
000.00
00000000000 000.00

00000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

00000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt m
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00000
000 0000-00-00
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PhoreMost Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Venture Capital-Backed Cambridge, United Kingdom 000 00000 000000&0 00000
000000000 00000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 0 00000
0000 0000000000 Corporation Hayward, CA
000000 000000 Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
0000000 Formerly PE-Backed Beijing, China 0000 00.000 00000000000 00.000
You’re viewing 5 of 45 competitors. Get the full list »

PhoreMost Executive Team (10)

Name Title Board Seat Contact Info
Christopher Torrance Ph.D Co-Founder, Board Member and Chief Executive Officer
Andrew Muncey Chief Financial Officer
Neil Torbett Ph.D Chief Operating Officer
Benedict Cross Ph.D Chief Technology Officer
Grahame McKenzie Ph.D Co-Founder and Chief Scientific Officer
You’re viewing 5 of 10 executive team members. Get the full list »

PhoreMost Board Members (11)

Name Representing Role Since
Alastair Kilgour Parkwalk Advisors Board Member 000 0000
Ashok Venkitaraman Ph.D PhoreMost Co-Founder, Chief Scientific Adviser and Board Member 000 0000
Catherine Beech MD PhoreMost Chairman 000 0000
Christopher Torrance Ph.D PhoreMost Co-Founder, Board Member and Chief Executive Officer 000 0000
Gerald Chan Ph.D Morningside Group Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

PhoreMost Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhoreMost Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Astellas Venture Management Corporate Venture Capital Minority 000 0000 000000 0
BGF Growth/Expansion Minority 000 0000 000000 0
Trend Investment Group Other Minority 000 0000 000000 0
XtalPi VC-Backed Company Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »